Loading…
Tarsus Pharmaceuticals, Inc. is projected to rise to $68.90 by 2027, a +19% move from its current price of $58.14. TARS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $56.24 | $58.15 | $60.13 | +0.02% |
| Jul 13 | $55.47 | $58.16 | $60.98 | +0.04% |
| Jul 14 | $54.89 | $58.17 | $61.65 | +0.05% |
| Jul 15 | $54.41 | $58.18 | $62.21 | +0.07% |
| Jul 16 | $53.99 | $58.19 | $62.72 | +0.09% |
| Jul 17 | $53.62 | $58.20 | $63.18 | +0.11% |
| Jul 18 | $53.28 | $58.21 | $63.61 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $53.28 | $58.21 | $63.61 | +0.13% |
| Week 2 | $51.42 | $58.29 | $66.07 | +0.25% |
| Week 3 | $50.06 | $58.36 | $68.04 | +0.38% |
| Week 4 | $48.94 | $58.43 | $69.76 | +0.51% |
| Week 5 | $47.99 | $58.51 | $71.33 | +0.63% |
| Week 6 | $47.15 | $58.58 | $72.78 | +0.76% |
| Week 7 | $46.40 | $58.66 | $74.15 | +0.89% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for eye care in the United States. It offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by Demodex mites.
The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. It is developing the lotilaner API to address diseases in human medicine, including eye care and infectious disease prevention.
Tarsus has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. The company was incorporated in 2016 and is headquartered in Irvine, California.
Tarsus Pharmaceuticals, Inc. (TARS) is currently trading with a price of $58.14 and a market capitalization of $2.54B. It ranks 1874 by market cap and operates within the Healthcare sector.
The asset’s price outlook shows a near-term neutral stance in 2026, with a gradual bullish trajectory into the late 2020s and beyond, supported by strong long-term forecast figures.
Forecasts place the 2026 range at min $57.41, avg $58.14, max $72.03 with 0% ROI and a Neutral sentiment. The path continues with higher averages and ROIs in 2027 ($68.90 avg, ROI 18.5), 2028 ($83.24 avg, ROI 43.2), and 2029 ($96.97 avg, ROI 66.8), culminating in 2030 with an avg of $107.35 and ROI 84.6. By 2050 the forecast envisions an avg of $435.80 and a max of $873.53, with a 649.6% ROI and a Bullish sentiment.
A major floor 15.9% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.3% away) — a key level to hold.
The nearest ceiling, 21.3% above — a clean break opens room to run.
A major ceiling 31.7% above — clearing it would confirm fresh momentum.
Key TARS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TARS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $65.52 | Sell | $63.40 | Sell |
| MA 10 | $64.11 | Sell | $64.02 | Sell |
| MA 20 | $63.76 | Sell | $63.67 | Sell |
| MA 50 | $62.53 | Sell | $63.67 | Sell |
| MA 100 | $65.77 | Sell | $64.91 | Sell |
| MA 200 | $68.98 | Sell | $64.12 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 40.82 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -166.71 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.21 | Sell |
| ROC (12) | -12.14 | Sell |
| Bollinger %B (20,2) | 0.00 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.18 | Buy |
| Awesome (5,34) | 3.22 | Buy |
| Ultimate (7,14,28) | 42.12 | Neutral |
| Momentum (10) | -6.20 | Sell |
| Aroon Osc (25) | -12.00 | Sell |
| Hull MA (9) | 65.22 | Sell |
| ADX (14) | 12.98 | Neutral |
| ATR (14) | 2.23 | Info |
The 30-day technical picture is Bearish with RSI(14) at 40. The stock trades with SMA50 at $62.53 and SMA200 at $68.98, indicating near-term softness versus longer-term trend lines. Support is seen at $57.41 and resistance at $70.55, shaping a concise trading range.
Over the last 30 days, the price has fluctuated between a low of $46.62 and a high of $72.50, highlighting modest volatility. Overall, the current setup suggests limited downside risk around the $57 area, but upside momentum could be constrained until a break above $70.55.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $57.41 | $58.14 | $72.03 | 0% | Neutral | |
| $53.69 | $68.90 | $94.21 | +19% | Neutral | |
| $62.63 | $83.24 | $118.91 | +43% | Bullish | |
| $70.86 | $96.97 | $143.35 | +67% | Bullish | |
| $76.43 | $107.35 | $163.29 | +85% | Bullish | |
| $71.29 | $102.54 | $159.89 | +76% | Bullish | |
| $76.92 | $113.13 | $180.37 | +95% | Bullish | |
| $80.99 | $121.64 | $197.88 | +109% | Bullish | |
| $77.03 | $118.04 | $195.57 | +103% | Bullish | |
| $99.18 | $154.94 | $261.13 | +166% | Bullish | |
| $113.45 | $193.64 | $350.38 | +233% | Bullish | |
| $218.15 | $435.80 | $873.53 | +650% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $57.41 | $58.14 | $68.42 | +0.00% |
| August 2026 | $48.28 | $57.35 | $70.21 | -1.36% |
| September 2026 | $49.33 | $59.10 | $73.33 | +3.06% |
| October 2026 | $47.74 | $57.62 | $72.30 | -2.52% |
| November 2026 | $45.49 | $55.25 | $69.99 | -4.10% |
| December 2026 | $46.14 | $56.38 | $72.03 | +2.04% |
Click any year to see its month-by-month TARS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect TARS to range from $57.41 to $72.03 through 2026. The $58.14 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The TARS price prediction for 2027 points to an average of $68.90 (low $53.69, high $94.21) — a potential gain of +19% on today's $58.14. Price action looks broadly range-bound.
In 2028, TARS is projected to trade between $62.63 and $118.91, averaging $83.24 — a potential gain of +43% from today's $58.14. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
Tarsus Pharmaceuticals, Inc.'s 2029 outlook centres on $96.97, within a $70.86 to $143.35 range. That is up +17% on the projected 2028 average. That marks a +67% change versus current levels. Momentum favours further upside here.
By 2030, TARS could reach as high as $163.29, with a base case around $107.35 and support toward $76.43 — roughly +85% from $58.14. Buyers look set to stay in control over this stretch.
Expect TARS to range from $71.29 to $159.89 through 2031. The $102.54 average target implies a +76% move from current prices. That is -4% versus the projected 2030 average. Momentum favours further upside here.
The TARS price prediction for 2032 points to an average of $113.13 (low $76.92, high $180.37) — a potential gain of +95% on today's $58.14. Buyers look set to stay in control over this stretch.
In 2033, TARS is projected to trade between $80.99 and $197.88, averaging $121.64 — a potential gain of +109% from today's $58.14. That is up +8% on the projected 2032 average. Momentum favours further upside here.
Tarsus Pharmaceuticals, Inc.'s 2034 outlook centres on $118.04, within a $77.03 to $195.57 range. That is -3% versus the projected 2033 average. That marks a +103% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, TARS could reach as high as $261.13, with a base case around $154.94 and support toward $99.18 — roughly +166% from $58.14. Momentum favours further upside here.
Expect TARS to range from $113.45 to $350.38 through 2040. The $193.64 average target implies a +233% move from current prices. That is up +25% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The TARS price prediction for 2050 points to an average of $435.80 (low $218.15, high $873.53) — a potential gain of +650% on today's $58.14. Momentum favours further upside here.
Investing $1,000 in TARS today (≈ 17.199862 TARS) could be worth
$7,495.73
+$6,495.73 (+650%) by 2050 · US Dollar
Based on the average projected TARS price of $435.8 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TARSwould be worth at today's price.
$1,000 invested in TARS on Jul 10, 2025 (≈ 24.295433 TARS) would be worth
$1,412.54
+$412.54 (+41.3%) today · 1.41× · US Dollar
Based on a TARS entry price of $41.16 vs. today's $58.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $65.44 | $888.45 | -11.2% |
| 1 month ago | $61.27 | $948.91 | -5.1% |
| 3 months ago | $72.56 | $801.27 | -19.9% |
| 6 months ago | $75.53 | $769.76 | -23.0% |
| 1 year ago | $41.16 | $1,412.54 | +41.3% |
| All time (5.0y) ago | $28.93 | $2,009.68 | +101.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TARS forecast.
Our base-case forecast reaches $120.00 around 2033.
Implied market cap at $120.00: $5.24B
Multi-year forecasts project a bullish trajectory for TARS, with notable upside in the mid-to-late 2020s and beyond. The 2030 forecast shows an avg price of $107.35 with an 84.6% ROI, underscoring meaningful appreciation from current levels. The 2040 forecast rises to an avg of $193.64 (ROI 233.1), and by 2050 the avg price is projected to $435.80 with a 649.6% ROI, signaling substantial long-term upside.
Key longer-term milestones include 2040 with a projected avg of $193.64 and 2050 with an avg of $435.80. These figures imply bullish momentum over the longer horizon, though they come with inherent uncertainty and are not guarantees. The forecast also indicates increasing price potential across the spectrum of years, culminating in strong upside by 2050.
Tap a question to reveal the answer.
2030 min $76.43, avg $107.35, max $163.29; ROI 84.6%; sentiment BULLISH.
Forecasts point to a bullish long-term trend, with rising averages and ROIs through 2027–2030 (e.g., 2027 avg $68.90, ROI 18.5; 2030 avg $107.35, ROI 84.6). Near term remains neutral initially, and forecasts are estimates, not guarantees.
Yes. The 2029 forecast shows an avg of $96.97 with a max of $143.35, and the 2030 forecast shows an avg of $107.35 with a max of $163.29, indicating potential to exceed $100 by 2029–2030.
Current price is $58.14 and market cap is $2.54B.
The 30-day range is from a low of $46.62 to a high of $72.50.
Tarsus Pharmaceuticals, Inc. Community Discussion
0Share your Tarsus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.